GSK’s risvutatug rezetecan shows 18.5-month median overall survival in phase 3 SCLC trial

GSK, together with Chinese partner Hansoh Pharma, reported results of its antibody‑drug conjugate risvutatug rezetecan (ris‑rez) in a phase 3 trial for relapsed small‑cell lung cancer.

The study enrolled 461 patients in China who had progressed after first‑line platinum therapy. Patients received the B7‑H3‑directed ADC every three weeks versus standard topotecan chemotherapy.

Median overall survival was 18.5 months for the ris‑rez group compared with 10.3 months for topotecan, meeting the primary endpoint and representing a statistically significant improvement.

The outcome positions the GSK‑Hansoh ADC as a potential competitor to similar agents from Amgen and Merck, which have reported median survivals of 13.6 months and 12.0 months respectively in their own trials.